Higher-risk APS: do we dare to DOAC?
Blood
.
2018 Sep 27;132(13):1357-1358.
doi: 10.1182/blood-2018-08-867036.
Authors
Marissa Laureano
1
,
Mark A Crowther
1
Affiliation
1
McMaster University.
PMID:
30262580
DOI:
10.1182/blood-2018-08-867036
No abstract available
Publication types
Comment
MeSH terms
Anticoagulants
Antiphospholipid Syndrome*
Humans
Rivaroxaban
Stroke*
Warfarin
Substances
Anticoagulants
Warfarin
Rivaroxaban